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Semen is the major source of infectious virus during sexual
transmission of human immunodeﬁciency virus type 1 (HIV-1). High
viral loads in semen have been detected in clade B HIV-1-infected
subjects at all stages of the disease (Gupta et al., 1997). However,
correlation of seminal viral loads with CD4+ T cell counts is
controversial. In some studies, there was a correlation between CD4
cell number and seminal viral loads (Vernazza et al., 1997) and in
other studies only a weak associationwas noticed (Gupta et al., 1997).
There is ample evidence to indicate that HIV-1 populations in semen
and blood are biologically and genetically different in clade B-infected
US and Western European subjects (Byrn and Kiessling, 1998; Coombs
et al., 1998; Delwart et al., 1998;Dyer et al., 1998; Gupta et al., 2000; Zhu
et al., 1996).We have recently demonstrated that the HIV-1 population
in semen in US subjects is further sub-compartmentalized between
seminal leukocytes and seminal plasma (Paranjpe et al., 2002). Such
sub-compartmentalization of HIV-1 populations between seminal cells
and seminal plasma was detected as early as 3 months after serocon-
version and persisted up to 38 months following seroconversion(Paranjpe et al., 2002). Despite these interesting and important ﬁndings
no studies have been done to date on the characterization of HIV-1 in
semen in non-B-infected subjects, although there are indications that
blood and seminal viral load may be higher in clade C-infected subjects
compared to clade B-infected subjects (Dyer et al., 1998).
India, with predominantly HIV-1 clade C (Cassol et al., 1996;
Delwart et al., 1998; Maitra et al., 1999; Mandal et al., 2002; Mandal
et al., 2000; Shankarappa et al., 2001; Tripathy et al., 1996) and the
rapid spread of HIV-1 infection, provides an excellent opportunity to
study the seminal viral load in disease progression in clade C-infected
subjects. Furthermore, genetic analysis of HIV-1 circulating in dif-
ferent parts of India indicates that clade C sequences from different
parts of India are more closely related to each other than to clade C
sequences from Botswana, Burundi, South Africa, Tanzania and
Zimbabwe. Hence, the Indian clade C is different than the clade C
circulating in other parts of the world (Shankarappa et al., 2001).
Interestingly, co-receptor switch from CCR5 to CXCR4 observed with
disease progression in clade B-infected subjects has never been
observed in clade C-infected subjects in India (Cecilia et al., 2000). In
addition, more rapid disease progression was observed in HIV-1-
infected seroconverters in India than seroconverters in US (Mehen-
dale et al., 2002). These differences in biologic and genetic properties
as well as disease progression between clade B- and C-infected
subjects raises the possibility that viral dynamics of HIV-1 in various
body compartments in clade C-infected subjects in India are different
Table 1
Quantitation of HIV-1 RNA in blood and semen (cross-sectional, ART naïve patients,
N=47).
HIV-1 RNA (103copy/ml)
Subject no. CD4 no.(cells/mm3) Blood plasma Seminal plasma
1 487 1157 101
2 654 5475 220
3 526 12, bADL
4 294 1759 64
5 483 64 bADL
6 293 bADL bADL
7 294 bADL bADL
8 265 2 bADL
9 171 167 22
10 26 276 12
11 176 2461 2943
12 241 bADL bADL
13 16l 1077 3
14 263 63 8
15 203 582 6
17 263 bADL bADL
18 432 bADL bADL
21 681 238 bADL
25 492 1478 282
27 175 25,072 790
28 212 4563 120
29 12 4 bADL
34 156 136 19
35 57 43 3
36 92 11,619 779
37 92 2161 30,569
38 468 158 8
39 76 10,174 381
40 365 13 bADL
41 294 4016 383
42 309 NA 3
43 139 4013 208
44 640 bADL bADL
45 121 1718 3222
47 200 16,841 269,481
48 592 3359 164
49 312 6146 1710
50 322 90 bADL
51 543 15 bADL
52 522 13 bADL
53 131 416 29
54 215 54 11,327
55 458 83 113
56 471 44 bADL
58 174 13 181
59 73 bADL bADL
60 132 9 bADL
NA sample not available.
bADL below assay detection limit.
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number of studies have demonstrated a dramatic reduction of viral
load in both semen and blood following antiretroviral therapy in HIV-
1 clade B-infected subjects (Barroso et al., 2003; Barroso et al., 2000;
Craigo et al., 2004; Gupta et al., 1997; Liuzzi et al., 1999; Liuzzi et al.,
2003; Vernazza et al., 1997; Zhang et al., 1998). However, there is little
information on the effect of antiretroviral therapy on viral load in
semen in clade C-infected subjects from India.
In this report we describe an in depth analysis of HIV-1 present in
semen and its fate following antiretroviral therapy in clade C HIV-1
infected subjects from India. We demonstrate that seminal viral load is
positively correlatedwith bloodplasmaviral load.Neither bloodplasma
viral nor seminal plasma viral load had any signiﬁcant correlation with
CD4 cell number. However, viral load in these two body compartments
is reduced drastically following antiretroviral therapy. Additionally,
viral variants in semen and blood are highly compartmentalized.
Results
Viral load in semen and blood from therapy naïve patients
HIV-1 viral loads in paired seminal and blood plasma samples
collected at individual visits were measured by TaqMan RT Real-Time
PCR with Indian clade C speciﬁc primers and probe described
previously (Ding et al., 2009). This assay has a range of detection of
1×103 to 3×1010 copies/ml utilizing 200 µl of plasma or semen. Of
the 47 randomly selected therapy-naïve subjects 61.7% (29/47) had
detectable HIV-1 RNA in seminal plasma, whereas 84.8% (39/46,
1=NA) subjects had detectable viral RNA in blood plasma. The viral
load in this therapy-naïve population ranged from 2.63×103 to
2.69×108 copies per ml (median 1.64×105) in seminal plasma and
from 1.85×103 to 2.5×107 copies per ml (median 2.76×105) in blood
plasma (Table 1). HIV-1 was not detected in 10 seronegative subjects
(data not shown). Seminal plasma viral load correlated signiﬁcantly
with blood plasma viral load (r2=0.59 and pb0.001) with Spearman
rank correlation of 0.81 (data not shown).
In this cross-sectional study high seminal viral load was present at all
stages of the diseasewith varying CD4 number (Table 1). Sincewe do not
have information on number of CD4 cells in semen due to low semen
samplevolume,wedeterminedcorrelationof seminal andbloodviral load
with blood CD4. HIV-1 RNA level in seminal plasma and in blood plasma
did not correlate signiﬁcantly with CD4 cell number (r2=0.05 with
p=0.151 and r2=0.02 with p=0.722, respectively) (data not shown).
Effect of antiretroviral therapy on viral load in semen and blood
compartments
Treatment of HIV-1 clade B-infected subjects with potent
antiretroviral therapy has been shown to reduce viral load in both
semen and blood compartment within 4 weeks of post therapy. To
determine whether such therapy reduces viral load in semen in HIV-1
clade C-infected subjects from India, we ﬁrst examined in a cross-
sectional study viral load in 15 subjects following therapy for a
varying length of time (0.5 month to 32 months) (Table 2). HIV-1 RNA
was detected only 20.0% (3/15) in seminal plasma and 26.7% (4/15)
in blood plasma from the drug treated subjects. The viral load in
seminal and blood plasma in response to therapy are summarized in
Fig. 1. In a longitudinal study viral load was measured in paired semen
and blood compartments of 4 HIV-1 clade C-infected Indian subjects
before and after therapy for a period of 1 to 19 months with a
combination of Lamivudine, Stavudine and Nevarpine. The level of
viral RNA in seminal plasma and blood plasma in these subjects was
reduced drastically to undectable level after 4 to 8 weeks of therapy
and remained below detectable limit for a period of up to 19 months
(Table 3). In one patient (patient 37) viral load in semen did not
reduce to undetectable limit within 5 months of treatment, althoughviral load in blood compartment was reduced to undetectable limit
during that period of time. This could be due to difference in drug
penetration in male genital organ between patients.
Sequence analysis of HIV-1 from cells and plasma from semen and blood
in drug naïve patients
Concurrent blood and semen samples obtained from 7 drug naïve
subjects were used in the study. Sequences from four compartments:
blood plasma and cells, as well as seminal plasma and cells were
obtained from four patients (subject number 4, 9, 11, and 14), while
sequences from three compartments blood plasma, seminal plasma
and seminal cells were obtained from three patients (subject number
2, 37, and 40). A total of 490 nucleotide sequences of a 680 bp seg-
ment encompassing the C2–V5 region of the HIV-1 gp120 from these
body compartments were analyzed from the seven patients. All the
sequences were screened by the BLAST program from HIV database
to rule out potential cross-contamination. Furthermore, sequences
Table 2
Quantitation of HIV-1 RNA in blood and semen after potent antiretroviral therapy
(cross-sectional samples, N=15).
HIV-1 RNA (103 copy/ml)
Subject no. Month
post-therapy
CD4 no.
(cells/mm3)
Blood plasma Seminal plasma
16 28 392 bADL bADL
19 2 281 bADL bADL
20 9 251 bADL bADL
22 11 121 bADL bADL
23 32 510 bADL bADL
24 17 266 bADL 5
26 2 89 1 bADL
30 2 30 bADL 213
31 17 319 bADL bADL
32 17 128 bADL bADL
33 21 156 236 bADL
46 0.5 100 24 bADL
57 7 181 bADL bADL
45-1 1 bADL 5
53-1 1 2 bADL
bADL below assay detection limit.
Table 3
Longitudinal paired semen and blood compartments of 4 HIV-1 clade C-infected
subjects before and after therapy.
HIV-1 RNA (103 copy/ml)
Subject no. Month
post-therapy
CD4 no.
(cells/mm3)
Blood plasma Seminal plasma
34-0 0 156 136 19
34-2 4 bADL bADL
34-3 8 344 bADL 38
34-4 12 331 bADL bADL
34-5 15 444 bADL bADL
34-6 17 337 bADL bADL
34-8 19 bADL bADL
37-0 0 92 2161 30,569
37-1 1 NA 15
37-2 5 268 bADL 11
39-0 0 76 10,174 381
39-1 1 44 37
39-2 4 561 bADL bADL
39-3 11 460 bADL bADL
39-5 14 bADL bADL
39-6 16 bADL bADL
58-0 0 174 13 181
58-1 2 bADL bADL
58-2 8 237 bADL bADL
NA sample not available.
bADL below assay detection limit.
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(data not shown), indicating no sample mixing or cross-contamination.
Genotyping and recombination analysis showed that all the patients
belonged to clade C, and did not have any contamination from other
HIV-1 clades.
Compartmentalization of HIV-1 between semen and blood of drug naïve
patients
The cladistic method of the Slatkin–Maddison test for compart-
mentalization among the four body compartments (seminal plasma,
seminal cells, blood plasma, blood cells) indicated signiﬁcant
phylogenetic compartmentalization (Pb0.0001) in all seven patients
at varying levels of stringency with themajority of patients having≤6
steps resolving the phylogenetic structure of four compartments
(Table 4). To conﬁrm the phylogenetic results, we used Gene Flow
calculations to estimate genetic migration Fst and Nm values among
all the seven patients. Nm values in six of the seven patients were
indicative of compartmentalization demonstrating restricted gene
ﬂow with Nm values ranging from 1.49 to 8.6 (Table 4). As observed
with the phylogenetic analyses this compartmentalization varied
among patients at the level of restriction, especially with patient 2
which demonstrated no migration restrictions with a Nm=109.35.
Taken together these data indicate signiﬁcant compartmentalization
in six of the seven patients.
Genetic diversity of individual compartment in drug naïve patients
Genetic diversity of individual compartment was calculated based
on distance measurements obtained by using the Jukes Cantor matrixFig. 1. Viral load of blood plasma and seminal plasma before and after potent anti-
retroviral therapy. Limit of detection is 1,000 copies/ml.from PAUP* software package. The blood plasma and seminal plasma
compartments display higher diversity than the blood cell and
seminal cell compartments respectively (Pb0.05) (Fig. 2A). Also, the
intracompartmental distance within the seminal compartment is
higher than the distance within the blood compartment (Pb0.01)
(Fig. 2B). Since HIV-1 from blood plasma is derived from HIV-1 in
blood cells, there will be less diversity between them, as compared to
seminal cells and seminal plasma which may have different origins
(Paranjpe et al., 2002).Immune selection pressure analysis in drug naïve patients
The rates of synonymous (dN) and nonsynonymous (dS) nucle-
otide substitutions per site of codon aligned nucleotide sequences in
the individual compartment populations were calculated by using
programDnaSP V4.50.3. The results showed a ratio of dN/dSb1 for the
whole C2–V5 sequences in all the four compartments: blood plasma,
blood cells, seminal plasma and seminal cell (0.841, 0.828, 0.875, and
0.853 respectively), suggesting no immune selection in either semen
and blood compartments. However, analysis of various subgenomic
regions of the C2–V5 region, such as C2, V3, C3, V4, C4, and V5, showed
positive immune selection in some regions and such immune
selection is different in different compartments (Fig. 3). As expectedTable 4
Phylogenetic compartmentalization analysis using MacClade and DnaSP.
DnaSP MacClade
Subjects Nm Fst Steps P
2 109.35 0.0023 2 b0.0001
4 1.53 0.14 4 b0.0001
9 1.61 0.13 5 b0.0001
11 8.6 0.03 8 b0.0001
14 2.85 0.08 6 b0.0001
37 1.85 0.12 4 b0.0001
40 1.49 0.14 3 b0.0001
Fig. 2. Diversity and distance analysis of envelope sequences (C2–V5) of HIV-1 from Indian patients using PAUP* software. (A) Nucleic acid diversity of corrected intrapopulation
diversity was calculated for nucleotide sequences. The quartile (box) differences between the diversity of all sequence clones were plotted as interpopulation distances as a function
of different compartments. (B) Corrected population distance between blood derived plasma and cells and semen derived plasma and cells was calculated for nucleotide sequences.
Statistical signiﬁcance of the differences between different compartments for each analysis was performed using nonparametric statistics, theMann–Whitney test. BP, blood plasma;
BC, blood cells; SP, semen plasma; SC, semen cells. Blood compartment, distance between blood plasma and blood cells; Semen compartment, distance between seminal plasma and
seminal cells.
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In addition, C2 and C3 regions of seminal cells and seminal plasma
showed positive selection. In contrast, V4 and V5 regions had no
positive immune selection.Co-receptor usage prediction and glycosylation in drug naïve patients
Because it is difﬁcult to isolate infectious HIV-1 from semen, co-
receptor usage of the HIV-1 in blood and semen compartments was
determined based on the deduced basic amino acid substitution in the
V3 region using software PSSM and geno2pheno. Consistent with
previous study (Cecilia et al., 2000), all of the viruses in all the four
compartments are R5 co-receptor usage and NSI.
To determine the variation in immune selection, glycosylation
patterns across the C2–V5 region were examined. N-glycosylations
have been implicated in the suppression of natural killer (NK) cell-
mediated responses, and the suppression of innate immune responses
involving NK cells that may be responsible for initiating AIDS path-
ogenesis (Kottilil et al., 2003; Yoshimura et al., 1996) Cell-speciﬁcFig. 3. Immune selection analysis of subgenome of C2–V5. Analysis of immune selection at v
from four body compartments (seminal cells and plasma, and blood cells and plasma).glycosylation proﬁles may affect immune susceptibility, and AIDS
progression may be related to the glycobiology of the virus (Clark
et al., 1997). Surprisingly, we did not ﬁnd any special pattern of N-
linked glycosylation among the four compartments (data not
shown).Discussion
Although there are a number of reports characterizing HIV-1 in
semen and the effects of antiretroviral therapy on HIV-1 in semen
in HIV-1 clade B-infected subjects in the US and in Western Europe,
similar information on HIV-1 clade C-infected subjects is scarce.
Since India harbors mainly HIV-1 clade C characterized by different
biologic and genetic properties (Shankarappa et al., 2001), we
launched a study investigating the genetics of HIV-1 in semen and
the effect of therapy on male genital secretion in 62 HIV-1-infected
subjects from India. In therapy naïve subjects we found a high level
of HIV-1 RNA in seminal plasma (median 1.64×105) at all stages of
the disease with CD4 ranging from 12 cells/mm3 to 681 cells/mm3.arious subgenomic regions (C2, V3, C3, V4, C4, and V5) of the whole C2–V5 sequences
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median blood plasma viral load (2.76×105), although in approxi-
mately 13% of patients (6/47) viral load in seminal plasma is higher
than those in blood. Furthermore, neither the seminal nor blood
plasma viral load correlated with blood CD4 cell numbers. Similar
data have been observed in semen from clade B HIV-1 infected
subjects (Gupta et al., 1997).
Three years ago the Indian government launched a limited
combination antiretroviral therapy composed of Lamivudine, Stavu-
dine and Nevarpine. Thus far, very little information is available on the
effect of such therapy on viral load in blood or semen in HIV-1 infected
subjects from India. In this report we have demonstrated that
treatment of HIV-infected subjects with highly active combination
antiretroviral therapy can promptly reduce the viral load in semen in
parallel with that in blood plasma. However, we do not have any
information on infectious viral titers or proviral DNA in seminal
mononuclear cells from subjects on therapy. This is the ﬁrst report of a
reduction of viral load in semen and blood in clade C HIV-1 infected
subjects from India. Since clade C in India is different than the clade Cs
circulating in other parts of the world, this information is important to
support and extend ongoing therapy intervention program in India.
These ﬁndings have important implications for the biology of sexual
transmission of HIV-1 and its potential reduction by antiretroviral
therapy. At present, there is an ongoing HIVNET study to determine
whether HIV-1 transmission from the infected Indian subjects treated
with antiretroviral therapy is decreased.
Analysis of HIV-1 sequences in semen is critical to the study of the
viral variants that are involved in sexual transmission. Analysis of the
HIV-1 variants in semen and blood of the majority of the seven drug
naïve patients showed signiﬁcant compartmentalization of HIV-1
between seminal and blood compartments among six out of seven
subjects. However, the degree of compartmentalization varied from
subject to subject. Restricted viral migration between semen and
blood supports our previous data that HIV-1 in semen is produced
locally. Furthermore, sub-compartmentalization between seminal
cells and seminal plasma support our previous contention with
clade B HIV-1 that seminal plasma and seminal cell viruses may
originate from different genital tissue sites (Paranjpe et al., 2002).
Compartmentalization of HIV-1 between semen and blood
suggests that distinct viral variants in these two body compartments
may be a product of different rate of evolution due to different
selective pressure operating in these two body compartments. We
investigated this possibility by analyzing immune selection pressure
in semen and blood compartments. Our analysis of pairwise
comparisons of synonymous and nonsynonymous substitutions by
the conservative method of dN/dS indicate differential immune
selection between these two compartments. The study by Pillai (Pillai
et al., 2005) reported semen speciﬁc signature amino acids in clade B
HIV-1 infected subjects from US. Using the same methodology we did
not ﬁnd similar semen speciﬁc signature amino acids among our 7
clade C-infected subjects from India (data not shown). This difference
could be due to unique genetic and biologic characteristics of clade C
HIV-1 from India.
In one study cellular tropism has been implicated to have a role
in compartmentalization between semen and blood derived virus
from clade B HIV-1 infected subjects (Delwart et al., 1998). How-
ever, our recent study and those reported in the literature indicate
that HIV-1 in India are mostly of CCR5 tropic with non-syncytium-
inducing phenotype even when they are isolated at late stage of
infection (Cecilia et al., 2000). In agreement with these reports
only CCR5 genotype was detected in both semen and blood com-
partments and therefore cellular tropism did not have any role in
compartmentalization.
In summary, this report for the ﬁrst time describes high levels of
HIV-1 in semen from clade C HIV-1 infected Indian subjects at all
stages of the disease and potent antiretroviral therapy rapidly reducesviral load in semen in parallel with that in blood. In addition, this
report provides detailed genetic characterization of HIV-1 in semen
from clade C HIV-1 infected Indian subjects, showing that viral
variants present in semen are different than those in blood and
difference in evolution of HIV-1 variants in these two compartments
could be due to difference in immune selection pressure.Methods
Study population, semen and blood samples
This study was conducted according to the IRB approval of the
University of Pittsburgh. Cryopreserved paired semen and blood
specimens from a total of 62 HIV-1 infected individuals were received
from the Virology Department of the School of Tropical Medicine
(STM) in Calcutta, India from May 2006 to September 2008. The
subjects age distribution were 23 to 54 years old (mean=35). Of
these 62 subjects, cross-sectional samples were obtained from 47
antiretroviral therapy-naïve subjects and from 15 subjects treated
with combination antiretroviral drugs Lamivudine, Stavudine and
Nevarpine for varying period of time (from 0.5 to 32 months).
Detailed clinical history and CD4 numbers were available from most
of the subjects. Therapy naïve subjects had CD4 counts ranging from
681 cells/mm3 to 12 cells/mm3. Drug treated subjects had CD4 counts
ranging from 510 cells/mm3 to 30 cells/mm3. Longitudinal samples
were collected from 4 subjects before and after therapy for a period of
1 to 19 months post-therapy.
Samples were processed within 4 h of collection. Blood plasma
was prepared by centrifuging EDTA treated blood at 1200 g at room
temperature. Semen was processed within 4 h of collection. After
30 min incubation in ice, liqueﬁed semen was centrifuged for 10 min
at 800–1000 g at room temperature to collect seminal cells and
seminal plasma. Separated seminal cells and seminal plasma were
kept at−70 °C and later transported in dry ice from Calcutta to India.
Preliminary results indicate that transportation of semen and blood
plasma samples in dry ice does not cause any signiﬁcant change in
viral load in semen and blood (data not shown).Quantitation of HIV-1 RNA in semen and blood
Total RNAwas isolated from two hundredmicroliters of seminal or
blood plasma by Nuclisens Isolation Kit according to manufacturer
instructions (Biomerieux) and subjected to Real-Time RT-PCR speciﬁc
for Indian HIV-1 clade C as described previously (Ding et al., 2009). To
rule out the potential PCR contamination, a no-template control was
included in each PCR run in which the template was replaced with
same volume of Nuclease-free water. Each sample was run in
triplicate. A standard curve generated by known copy number of in
vitro transcribed HIV-1pol RNA gene was used for copy number
estimation. Assay detection limit is 1,000 copies/ml.Cloning and sequencing of C2–V5 region of HIV-1 env RNA
Total RNA was extracted from blood plasma, blood cells, semen
plasma and semen cells, and subjected to reverse transcription and
polymerase chain reaction (RT-PCR) of the C2–V5 region of the HIV-1
envelope as described previously (Delwart et al., 1993; Liu et al.,
1997). Negative controls were applied with each PCR run to detect
any possible contamination. For each sample, PCR products from ﬁve
independent PCR reactions were cloned into the TOPO XL vector from
the TOPO TA-Cloning system (Invitrogen, Carlsbad, CA). DNA from 15
to 20 screened clones were puriﬁed using the QIAprep® Spin
Miniprep Kit (Qiagen) and sequenced using primers for forward and
reverse directions in an ABI Prism 3700 DNA Sequencer.
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Sequences were assembled and error checked utilizing software
Vector-NTI (Invitrogen). Nucleotide and deduced amino acid
sequences from each clone were aligned using the Clustal W multiple
sequence alignment program from the MEGA4.0 software and edited
manually where necessary.
Genotyping and phylogenetic reconstruction
Genotyping was carried out in viral genotyping tools for
Recombinant Identiﬁcation Program: RIP 3.0 and Genotyping
from NCBI — http://www.ncbi.nlm.nih.gov/projects/genotyping/
formpage.cgi. The neighbor-joining method of Jukes Cantor corrected
nucleotide distances was employed to construct the phylogenetic
trees with the optimality criterion set to distance as measured in
PAUP4⁎ with a transition-to-transversion ratio of 2. Statistical
signiﬁcance of branchings and various clustering were assessed by
the bootstrap resamplingmethod using 1000 replicate. The trees were
viewed and edited for publication using FigTree version 1.1.2.
Evaluation of compartmentalization
Two separate methods were used to test for compartmentalization
of HIV-1 between the four body compartments: blood plasma, blood
cells, seminal plasma and seminal cells as described previously
(Paranjpe et al., 2002). First, software DnaSP V4.50.3.was utilized to
estimate the standard population genetic parameters. Genetic
differentiation among populations was evaluated by estimating Fst,
the fraction of nucleotide diversity as a result of genetic variation
between populations. Nm, the average level of gene ﬂow, among the
four compartments was conﬁrmed from Fst. The value of Nm equal or
less than 5 indicated signiﬁcant population subdivision among the
four compartments. Second, a cladistic method of Slatkin–Maddison
analysis (Slatkin andMaddison, 1989; Slatkin andMaddison, 1990) as
implemented in the MacClade 4 program was also used to assess
compartmentalization among these four compartments . A MacClade
data ﬁle listing all of the specimens was constructed for each patient
and each compartment was treated as a four-state unordered
character. The number of migration events needed to postulate the
observed spatial distribution of HIV-1 sequences in the phylogenetic
trees was estimated using MacClade. The null model of this analysis is
that sequences from one compartment would be as likely to be
evolutionarily related to sequences from other compartments as to
itself. The frequency of distribution under this null model was
obtained by constructing 10,000 random trees made by random
joining/splitting of the ‘true’ phylogenetic tree in MacClade. The
number of migration events on the true tree was compared to the null
distribution and the probability that the true tree came from a
population lacking compartmentalization was determined. Tissue
speciﬁc compartmentalization was considered statistically signiﬁcant
if fewer steps were seen in the true tree than in 95% of the random
trees.
Analysis of selection pressure at different regions and different sites
The rates of synonymous and nonsynonymous substitution in the
individual compartment populations were calculated by using
program DnaSP V4.50.3. First, we analyzed the whole C2–V5 region.
Second, we analyzed six regions C2, V3, C3, V4, C4, and V5 of the C2–
V5 region separately using the same program.
Co-receptor usage prediction and glycosylation
Software PSSM and geno2pheno were employed to predict co-
receptor usage and syncytium-inducing. They are available at http://ubik.microbiol.washington.edu/computing/pssm/ (Jensen et al., 2003) and
http://coreceptor.bioinf.mpi-inf.mpg.de/index.php (Sing et al., 2007).
Potential of N-linked glycosylation sites within each sequence was
predicted by software N-GlycoSite available at the HIV database website
(http://www.hiv.lanl.gov/content/sequence/GLYCOSITE/glycosite.html).
Statistical analysis
Virologic data were measured in copies per milliliter and immu-
nologic data were measured as cell number per millimeter cubed.
All variables were summarized using means and standard devia-
tions as well as medians and ranges. For statistical analyses, log
base 10 transformation of viral load data was used. In comparison of
viral loads in semen and plasma all values less than 1000 were set
to equal 1000. Correlations were calculated using a non-parametric
method (i.e., Spearman rank) and reported with associated p-
values. Further, linear regression was used to calculate an estimate
of rate of change (i.e., slope) between each pair of continuous
variables (e.g., CD4 and semen viral load). Slopes were reported
with associated p-values and r-squared values. All analyses were
conducted in STATA version 9
Nucleotide sequence accession numbers
Sequences were deposited in GenBank under the accession nos.
FJ541508–FJ541996.
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